dual glucagon/GLP-1 agonistGLP-1 AgonistsVerified Match
Survodutide
A dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim. In Phase 3 trials for obesity and MASH/NASH. Glucagon component adds thermogenic energy expenditure to GLP-1 appetite suppression.
weight-lossliver-fat-reductiondual-agonistNASH-treatmentexperimental
Lab Tested
Yes
Harmful Ingredients
0
Contaminants
None
Tested Purity
--
Batch Consistency
No batch data
Mass Spec Profile
ESI-MS (computed)
Batch Info
Latest Batch—
Total Tests7
Unique Vendors7
Vendor Comparison
| Vendor | Status |
|---|---|
U Uther | Verified |
A Anlv Biotechnology | Verified |
P Peptide-S | Verified |
Q Qing Li Peptide | Verified |
P Polaris Peptides | Verified |
Analysis Summary
Purity Standard
No purity dataLab Reports
7 reports on file
Summary
A dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim. In Phase 3 trials for obesity and MASH/NASH. Glucagon component adds thermogenic energy expenditure to GLP-1 appetite suppression.